NSAID use and the risk of Parkinson's disease.
Identifieur interne : 002730 ( Main/Exploration ); précédent : 002729; suivant : 002731NSAID use and the risk of Parkinson's disease.
Auteurs : Mahyar Etminan [Canada] ; Samy SuissaSource :
- Current drug safety [ 1574-8863 ] ; 2006.
English descriptors
- KwdEn :
- Aged, Anti-Inflammatory Agents, Non-Steroidal (adverse effects), Anti-Inflammatory Agents, Non-Steroidal (therapeutic use), Antiparkinson Agents (therapeutic use), Arthritis (drug therapy), Case-Control Studies, Cohort Studies, Drug Utilization, Female, Humans, Logistic Models, Male, Parkinson Disease (epidemiology), Risk, Saskatchewan (epidemiology).
- MESH :
- chemical , adverse effects : Anti-Inflammatory Agents, Non-Steroidal.
- chemical , therapeutic use : Anti-Inflammatory Agents, Non-Steroidal, Antiparkinson Agents.
- geographic , epidemiology : Saskatchewan.
- drug therapy : Arthritis.
- epidemiology : Parkinson Disease.
- Aged, Case-Control Studies, Cohort Studies, Drug Utilization, Female, Humans, Logistic Models, Male, Risk.
Abstract
Parkinson's disease (PD) is a neurodegenerative disease with limited pharmacologic therapies. Recent animal studies and one large retrospective study have found NSAIDs to be protective against the development of PD. We decided to test this hypothesis by conducting a nested case-control study using the Saskatchewan drug plan database. Entry to the cohort was defined as the first prescription of an antihypertensive agent between 1980 and 1987 and followed until 1999. Cases were defined as those having received three prescriptions for a dopamine agonist within a year. For each case, ten controls were selected matched to the case by age, calendar time and index date. Conditional logistic regression was used to estimate rate ratios adjusting for gender, previous use of arthritis medication and previous antipsychotic use. Current users of NSAIDs had a slightly higher risk of developing PD (RR=1.49 [95% CI, 1.11-2.01]). This effect was not seen with past users (RR=1.18 [95% CI, 0.89-1.59]). Based on the results of our study current users of NSAIDs may be at a slightly higher risk of developing PD. More studies are needed to confirm this finding.
PubMed: 18690932
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001152
- to stream PubMed, to step Curation: 001152
- to stream PubMed, to step Checkpoint: 001152
- to stream Ncbi, to step Merge: 000944
- to stream Ncbi, to step Curation: 000944
- to stream Ncbi, to step Checkpoint: 000944
- to stream Main, to step Merge: 002A08
- to stream Main, to step Curation: 002730
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">NSAID use and the risk of Parkinson's disease.</title><author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name><affiliation wicri:level="1"><nlm:affiliation>Center for Clinical Epidemiology and Evaluation, Vancouver Hospital, 828 W. 10th Avenue, Vancouver, BC, Canada. metminan@shaw.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Center for Clinical Epidemiology and Evaluation, Vancouver Hospital, 828 W. 10th Avenue, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Suissa, Samy" sort="Suissa, Samy" uniqKey="Suissa S" first="Samy" last="Suissa">Samy Suissa</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:18690932</idno><idno type="pmid">18690932</idno><idno type="wicri:Area/PubMed/Corpus">001152</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001152</idno><idno type="wicri:Area/PubMed/Curation">001152</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001152</idno><idno type="wicri:Area/PubMed/Checkpoint">001152</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001152</idno><idno type="wicri:Area/Ncbi/Merge">000944</idno><idno type="wicri:Area/Ncbi/Curation">000944</idno><idno type="wicri:Area/Ncbi/Checkpoint">000944</idno><idno type="wicri:doubleKey">1574-8863:2006:Etminan M:nsaid:use:and</idno><idno type="wicri:Area/Main/Merge">002A08</idno><idno type="wicri:Area/Main/Curation">002730</idno><idno type="wicri:Area/Main/Exploration">002730</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">NSAID use and the risk of Parkinson's disease.</title><author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name><affiliation wicri:level="1"><nlm:affiliation>Center for Clinical Epidemiology and Evaluation, Vancouver Hospital, 828 W. 10th Avenue, Vancouver, BC, Canada. metminan@shaw.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Center for Clinical Epidemiology and Evaluation, Vancouver Hospital, 828 W. 10th Avenue, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Suissa, Samy" sort="Suissa, Samy" uniqKey="Suissa S" first="Samy" last="Suissa">Samy Suissa</name></author></analytic><series><title level="j">Current drug safety</title><idno type="ISSN">1574-8863</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Anti-Inflammatory Agents, Non-Steroidal (adverse effects)</term><term>Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Arthritis (drug therapy)</term><term>Case-Control Studies</term><term>Cohort Studies</term><term>Drug Utilization</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Parkinson Disease (epidemiology)</term><term>Risk</term><term>Saskatchewan (epidemiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Saskatchewan</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Case-Control Studies</term><term>Cohort Studies</term><term>Drug Utilization</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Risk</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is a neurodegenerative disease with limited pharmacologic therapies. Recent animal studies and one large retrospective study have found NSAIDs to be protective against the development of PD. We decided to test this hypothesis by conducting a nested case-control study using the Saskatchewan drug plan database. Entry to the cohort was defined as the first prescription of an antihypertensive agent between 1980 and 1987 and followed until 1999. Cases were defined as those having received three prescriptions for a dopamine agonist within a year. For each case, ten controls were selected matched to the case by age, calendar time and index date. Conditional logistic regression was used to estimate rate ratios adjusting for gender, previous use of arthritis medication and previous antipsychotic use. Current users of NSAIDs had a slightly higher risk of developing PD (RR=1.49 [95% CI, 1.11-2.01]). This effect was not seen with past users (RR=1.18 [95% CI, 0.89-1.59]). Based on the results of our study current users of NSAIDs may be at a slightly higher risk of developing PD. More studies are needed to confirm this finding.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Suissa, Samy" sort="Suissa, Samy" uniqKey="Suissa S" first="Samy" last="Suissa">Samy Suissa</name></noCountry><country name="Canada"><noRegion><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002730 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002730 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18690932
|texte= NSAID use and the risk of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18690932" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |